ATB200-03: A PHASE 3 DOUBLE-BLIND RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INTRAVENOUS ATB200 CO-ADMINISTERED WITH ORAL AT2221 IN ADULT SUBJECTS WITH LATE ONSET POMPE DISEASE COMPARED WITH ALGLUCOSIDASE ALFA/PLACEBO
|Effective start/end date||8/1/19 → 12/31/20|
- Amicus Therapeutics
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.